세계의 특수 제네릭 시장 보고서(2025년)

Specialty Generics Global Market Report 2025

US $ 4,490 ￦ 6,242,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,023,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,803,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

특수 제네릭 시장 규모는 향후 몇 년 동안 연평균 15.1%의 성장률(CAGR)로 2029년까지 1,897억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 바이오시밀러 시장의 확대, 복잡한 제네릭 의약품 개발의 중요성, 특수 제네릭 주사제에 대한 관심 증가, 특수 제네릭 제조에 3D 프린팅 채택, 신흥 시장에서의 특수 제네릭의 성장에 기인합니다. 예측 기간 동안 주요 동향으로는 맞춤형 및 표적화된 특수 제네릭, 제네릭 의약품 개발의 전략적 파트너십 및 제휴, 오남용 억제제 개발의 중요성, 특수 제네릭의 디지털 헬스 기술 통합, 복잡한 제네릭 의약품의 승인 가속화를 위한 규제 당국의 노력 등이 있습니다.

만성질환의 증가는 특수 제네릭 의약품 시장의 수요를 증가시킬 것으로 예상됩니다. 만성질환은 관리 및 통제가 가능한 경우도 있지만, 대부분 불치병이 될 수 있는 장기적인 질병입니다. 생활습관의 변화, 식습관 장애, 부적절한 체중 관리 등의 요인이 만성질환의 확산에 기여하고 있으며, 만성질환의 장기화로 인해 암 발생 위험이 높아지는 경우도 있습니다. 이러한 질병 이환율의 증가는 복잡한 만성질환 치료에 대한 특수 제네릭의 필요성을 증폭시키고 있습니다. 예를 들어, 2022년 9월 스위스에 본부를 둔 유엔 전문기구인 세계보건기구(WHO)는 비감염성 질환(NCDs) 또는 만성질환으로 인한 사망자가 전 세계적으로 연간 4,100만 명에 달하며, 이는 전체 사망자의 74%를 차지한다고 보고했습니다. 그 중 심혈관질환으로 인한 사망이 1,790만 명, 암으로 인한 사망이 930만 명, 만성 호흡기질환으로 인한 사망이 410만 명, 당뇨병으로 인한 사망이 200만 명입니다. 따라서 만성질환의 급증은 특수 제네릭 시장의 성장에 박차를 가하고 있습니다.

인구 고령화는 향후 특수 제네릭 시장을 촉진할 것으로 예상됩니다. '고령화'는 사회 내 고령자 비율의 증가를 특징으로 하는 인구통계학적 변화를 의미합니다. 특수 제네릭은 수술 후 통증, 급성 감염, 단기 통증 완화 등 노인에게 많이 발생하는 급성 증상에 대처하기 위해 특별히 처방되는 의약품입니다. 2022년 10월 세계보건기구(WHO)의 예측에 따르면, 2030년에는 전 세계 인구 6명 중 1명이 60세 이상의 고령자가 될 것이며, 그 수는 14억 명에 달할 것으로 예상됩니다. 전 세계 60세 이상 인구는 두 배인 21억 명으로 증가할 것으로 예상됩니다. 따라서 고령화는 특수 제네릭 의약품 시장의 중요한 촉진요인입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 특수 제네릭 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
• 최종 이용 산업 분석
• 세계의 특수 제네릭 시장 : 성장률 분석
• 세계의 특수 제네릭 시장 실적 : 규모와 성장, 2019-2024
• 세계의 특수 제네릭 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계의 특수 제네릭 전체 시장(TAM)

제6장 시장 세분화

• 세계의 특수 제네릭 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 주입
• 경구
• 기타 투여 경로
• 세계의 특수 제네릭 시장 : 적응증별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 종양학
• 자가면역질환
• 감염증
• 기타 적응증
• 세계의 특수 제네릭 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 소매 약국
• 전문 약국
• 병원 약국
• 세계의 특수 제네릭 시장, 주사제 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 정맥내(IV) 주사제
• 근육내(IM) 주사제
• 피하주사 제
• 세계의 특수 제네릭 시장, 구강 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 정제
• 캡슐
• 액체 제제
• 세계의 특수 제네릭 시장, 기타 투여 경로 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 외용
• 경피
• 흡입

제7장 지역별·국가별 분석

• 세계의 특수 제네릭 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 특수 제네릭 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 특수 제네릭 시장 : 경쟁 구도
• 특수 제네릭 시장 : 기업 개요
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Endo International plc Overview, Products and Services, Strategy and Financial Analysis
  • Akorn Operating Company LLC Overview, Products and Services, Strategy and Financial Analysis
  • Mallinckrodt Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
  • Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업과 혁신적 기업

• Fresenius Kabi Brasil Ltda
• STADA Arzneimittel AG
• Cipla Limited
• Lupin Ltd
• Aurobindo Pharma Limited
• Aspen Pharmacare Holdings Limited
• Pfizer Inc.
• Accord Healthcare Limited
• Amneal Pharmaceuticals Inc.
• Sandoz International GmbH
• Zydus Lifesciences Ltd.
• Torrent Pharmaceuticals Ltd.
• Perrigo Company plc
• Impax Laboratories Inc.
• Par Pharmaceutical Companies Inc.

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 특수 제네릭 시장 2029 : 새로운 기회를 제공하는 국가
• 특수 제네릭 시장 2029 : 새로운 기회를 제공하는 부문
• 특수 제네릭 시장 2029 : 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

Specialty generics refer to generic versions of drugs designed to replicate expensive, intricate, or high-touch generic medications. Managing specialty generics requires substantial service participation. This category encompasses biologics and biosimilars, each with distinct regulatory routes. Specialty medications, in general, are commonly used to treat various conditions such as malignancies, rheumatoid arthritis, and multiple sclerosis.

Specialty generics are administered through various routes, including injectables, oral, and others. The injectables route involves diverse methods of drug administration such as intravenous, subcutaneous, intradermal, intraperitoneal, intramuscular, and others. This is applicable in the treatment of medical conditions ranging from cancer to autoimmune disorders. Drug injection typically involves the use of a hollow hypodermic needle to introduce a substance into the bloodstream. Specialty generics find applications in indications like oncology, autoimmune diseases, infectious diseases, and others. These medications are distributed through multiple channels, including retail pharmacies, specialty pharmacies, and hospital pharmacies.

The specialty generics market research report is one of a series of new reports from The Business Research Company that provides specialty generics market statistics, including specialty generics industry global market size, regional shares, competitors with a specialty generics market share, detailed specialty generics market segments, market trends and opportunities, and any further data you may need to thrive in the specialty generics industry. This specialty generics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The specialty generics market size has grown rapidly in recent years. It will grow from $95.87 billion in 2024 to $108.11 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to patent expirations of brand-name drugs, growing demand for cost-effective alternatives, regulatory support for generic drug approvals, increasing healthcare cost pressures, rise in chronic diseases and aging population.

The specialty generics market size is expected to see rapid growth in the next few years. It will grow to $189.72 billion in 2029 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to expansion of biosimilars market, emphasis on complex generic drug development, increasing focus on specialty generic injectables, adoption of 3d printing in specialty generic manufacturing, growth of specialty generics in emerging markets. Major trends in the forecast period include personalized and targeted specialty generics, strategic partnerships and collaborations in generic drug development, focus on developing abuse-deterrent formulations, integration of digital health technologies in specialty generics, regulatory initiatives for accelerated approval of complex generics.

The increase in chronic diseases is projected to boost the demand for the specialty generic market. Chronic diseases are long-term illnesses that are often incurable, although some can be managed or controlled. Factors such as changing lifestyles, poor eating habits, and inadequate weight management contribute to the prevalence of chronic conditions, with some extended chronic illnesses heightening the risk of cancer. The rising incidence of these diseases amplifies the need for specialty generics to treat complex chronic conditions. For example, in September 2022, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported that 41 million deaths annually-accounting for 74% of deaths from non-communicable diseases (NCDs) or chronic diseases-occur globally. This includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Therefore, the surge in chronic diseases is fueling the growth of the specialty generic market.

The aging population is expected to propel the specialty generic market in the future. The term 'aging population' denotes the demographic shift characterized by a rising proportion of elderly individuals in a society. Specialty generics are specifically formulated pharmaceuticals designed to address acute conditions prevalent in the elderly, such as postoperative pain, acute infections, or short-term pain relief. This ensures effective treatment options for the aging population while managing healthcare costs. According to the World Health Organization's projections in October 2022, by 2030, one out of every six individuals globally will be 60 years or older, reaching 1.4 billion. By 2050, the global population of individuals aged 60 and older is expected to double to 2.1 billion. Therefore, the aging population is a significant driver for the specialty generic market.

Major companies in the specialty generic market are obtaining approvals for medications like Lisdexamfetamine Dimesylate to address critical medical needs. Approval in specialty generics refers to the regulatory authorization granted to pharmaceutical products that are bioequivalent and therapeutically equivalent to brand-name specialty drugs. In August 2023, Mallinckrodt plc, an Ireland-based specialty pharmaceutical company, received FDA approval for Lisdexamfetamine Dimesylate Capsules in SpecGx LLC Specialty Generics segment to treat Attention-Deficit/Hyperactivity Disorder (ADHD). Lisdexamfetamine Dimesylate, a federally controlled substance (CII), is used for ADHD and other indications.

Major companies in the specialty generic market are introducing new products to offer more affordable alternatives. In March 2022, Teva Pharmaceutical Industries Ltd, an Israel-based pharmaceutical company, launched the first generic version of REVLIMID (lenalidomide) in the US, available in 5mg, 10mg, 15mg, and 25mg capsules. REVLIMID is prescribed for adults with multiple myeloma (MM) and is used either in combination with dexamethasone or as a maintenance treatment post-autologous hematopoietic stem cell transplantation.

In October 2022, Aspire Pharma, a UK-based pharmaceutical company, acquired Morningside Pharmaceuticals and Morningside Healthcare, including its subsidiaries like Morningside Healthcare (India), for an undisclosed amount. This strategic acquisition aims to expand Aspire Pharma's market position by combining complementary product portfolios, providing added talent, an increased in-market range, and an industry-leading pipeline, positioning the company as a premier specialty generic pharmaceutical organization.

Major companies operating in the specialty generics market include Teva Pharmaceutical Industries Ltd., Endo International plc, Akorn Operating Company LLC, Mallinckrodt Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Fresenius Kabi Brasil Ltda, STADA Arzneimittel AG, Cipla Limited, Lupin Ltd, Aurobindo Pharma Limited, Aspen Pharmacare Holdings Limited, Pfizer Inc., Accord Healthcare Limited, Amneal Pharmaceuticals Inc., Sandoz International GmbH, Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Perrigo Company plc, Impax Laboratories Inc., Par Pharmaceutical Companies Inc., Alvogen, Alkem Laboratories Ltd., Wockhardt Ltd., Strides Pharma Science Limited, Indoco Remedies Ltd., Unichem Laboratories Ltd., Alembic Pharmaceuticals Ltd., Jubilant Life Sciences Ltd.

North America was the largest region in the specialty generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specialty generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the specialty generics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The specialty generics market consists of sales of biologics and biosimilars. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Specialty Generics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on specialty generics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for specialty generics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The specialty generics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Route Of Administration: Injectables; Oral; Other Route Of Administration
• 2) By Indication: Oncology; Autoimmune Diseases; Infectious Diseases; Other Indication
• 3) By Distribution Channel: Retail Pharmacies; Specialty Pharmacies; Hospital Pharmaciesx
• Subsegments:
• 1) By Injectables: Intravenous (IV) Injectables; Intramuscular (IM) Injectables; Subcutaneous (SC) Injectables
• 2) By Oral: Tablets; Capsules; Liquid Formulations
• 3) By Other Route Of Administration: Topical; Transdermal; Inhalation
• Companies Mentioned: Teva Pharmaceutical Industries Ltd.; Endo International plc; Akorn Operating Company LLC; Mallinckrodt Pharmaceuticals; Dr. Reddy's Laboratories Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Specialty Generics Market Characteristics

3. Specialty Generics Market Trends And Strategies

4. Specialty Generics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Specialty Generics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Specialty Generics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Specialty Generics Market Growth Rate Analysis
• 5.4. Global Specialty Generics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Specialty Generics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Specialty Generics Total Addressable Market (TAM)

6. Specialty Generics Market Segmentation

• 6.1. Global Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectables
• Oral
• Other Route Of Administration
• 6.2. Global Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Other Indication
• 6.3. Global Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacies
• Specialty Pharmacies
• Hospital Pharmacies
• 6.4. Global Specialty Generics Market, Sub-Segmentation Of Injectables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV) Injectables
• Intramuscular (IM) Injectables
• Subcutaneous (SC) Injectables
• 6.5. Global Specialty Generics Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Capsules
• Liquid Formulations
• 6.6. Global Specialty Generics Market, Sub-Segmentation Of Other Route Of Administration, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical
• Transdermal
• Inhalation

7. Specialty Generics Market Regional And Country Analysis

• 7.1. Global Specialty Generics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Specialty Generics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Specialty Generics Market

• 8.1. Asia-Pacific Specialty Generics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Specialty Generics Market

• 9.1. China Specialty Generics Market Overview
• 9.2. China Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Specialty Generics Market

• 10.1. India Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Specialty Generics Market

• 11.1. Japan Specialty Generics Market Overview
• 11.2. Japan Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Specialty Generics Market

• 12.1. Australia Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Specialty Generics Market

• 13.1. Indonesia Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Specialty Generics Market

• 14.1. South Korea Specialty Generics Market Overview
• 14.2. South Korea Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Specialty Generics Market

• 15.1. Western Europe Specialty Generics Market Overview
• 15.2. Western Europe Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Specialty Generics Market

• 16.1. UK Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Specialty Generics Market

• 17.1. Germany Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Specialty Generics Market

• 18.1. France Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Specialty Generics Market

• 19.1. Italy Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Specialty Generics Market

• 20.1. Spain Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Specialty Generics Market

• 21.1. Eastern Europe Specialty Generics Market Overview
• 21.2. Eastern Europe Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Specialty Generics Market

• 22.1. Russia Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Specialty Generics Market

• 23.1. North America Specialty Generics Market Overview
• 23.2. North America Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Specialty Generics Market

• 24.1. USA Specialty Generics Market Overview
• 24.2. USA Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Specialty Generics Market

• 25.1. Canada Specialty Generics Market Overview
• 25.2. Canada Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Specialty Generics Market

• 26.1. South America Specialty Generics Market Overview
• 26.2. South America Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Specialty Generics Market

• 27.1. Brazil Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Specialty Generics Market

• 28.1. Middle East Specialty Generics Market Overview
• 28.2. Middle East Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Specialty Generics Market

• 29.1. Africa Specialty Generics Market Overview
• 29.2. Africa Specialty Generics Market, Segmentation By Route of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Specialty Generics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Specialty Generics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Specialty Generics Market Competitive Landscape And Company Profiles

• 30.1. Specialty Generics Market Competitive Landscape
• 30.2. Specialty Generics Market Company Profiles
  • 30.2.1. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Endo International plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Akorn Operating Company LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Mallinckrodt Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Specialty Generics Market Other Major And Innovative Companies

• 31.1. Fresenius Kabi Brasil Ltda
• 31.2. STADA Arzneimittel AG
• 31.3. Cipla Limited
• 31.4. Lupin Ltd
• 31.5. Aurobindo Pharma Limited
• 31.6. Aspen Pharmacare Holdings Limited
• 31.7. Pfizer Inc.
• 31.8. Accord Healthcare Limited
• 31.9. Amneal Pharmaceuticals Inc.
• 31.10. Sandoz International GmbH
• 31.11. Zydus Lifesciences Ltd.
• 31.12. Torrent Pharmaceuticals Ltd.
• 31.13. Perrigo Company plc
• 31.14. Impax Laboratories Inc.
• 31.15. Par Pharmaceutical Companies Inc.

32. Global Specialty Generics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Specialty Generics Market

34. Recent Developments In The Specialty Generics Market

35. Specialty Generics Market High Potential Countries, Segments and Strategies

• 35.1 Specialty Generics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Specialty Generics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Specialty Generics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료